Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
企業コードPLSE
会社名Pulse Biosciences Inc
上場日May 18, 2016
最高経営責任者「CEO」Mr. Paul A. Laviolette
従業員数75
証券種類Ordinary Share
決算期末May 18
本社所在地3957 Point Eden Way
都市HAYWARD
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号94545
電話番号15109064600
ウェブサイトhttps://www.pulsebiosciences.com/
企業コードPLSE
上場日May 18, 2016
最高経営責任者「CEO」Mr. Paul A. Laviolette
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし